Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02838979 · ClinicalTrials.gov registry record · Phase 2
Trial of Oral Glutamine on Mitochondrial Function in CKD
A Phase 2 study of Cardiovascular Disease and Endothelial Dysfunction, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02838979 is a Phase 2 study of Cardiovascular Disease and Endothelial Dysfunction that has completed, run by University of Washington. The registered enrollment target is 11 participants, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02838979, a Phase 2 study of Cardiovascular Disease and Endothelial Dysfunction, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of proposed investigation is to study the impact of oral glutamine supplementation on muscle mitochondrial and endothelial cell function measured mitochondrial energetics and vascular function using 31P magnetic resonance spectroscopy and optical spectroscopy (MRS/OS) among persons with moderate-severe CKD. The secondary objective is to describe the impact of oral glutamine supplementation on mitochondrial metabolic profile as well as inflammatory and oxidative stress biomarkers among persons with chronic kidney disease.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT First Intervention (14 days)
- OTHER Washout (3 weeks)
- DIETARY_SUPPLEMENT Second Intervention (14 days)
Study Locations (1)
Washington
- Kidney Research Institute, University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-02-25 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02838979
The ClinicalTrials.gov registry entry for NCT02838979 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (100% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 3 interventions - of which First Intervention (14 days) is the first listed.
NCT02838979 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT02838979 about?
NCT02838979 is a clinical study titled "Trial of Oral Glutamine on Mitochondrial Function in CKD". The primary goal of proposed investigation is to study the impact of oral glutamine supplementation on muscle mitochondrial and endothelial cell function measured mitochondrial energetics and vascular function using 31P magnetic resonance spectroscopy and optical spectroscopy (MRS/OS) among persons ...
What is the current status of trial NCT02838979?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2016-02-25. Estimated completion is 2018-01-31.
What conditions does trial NCT02838979 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Endothelial Dysfunction, Sarcopenia, Kidney Disease, Muscle Mitochondrial Function.
What interventions are being tested in trial NCT02838979?
The interventions under investigation include: First Intervention (14 days) (DIETARY_SUPPLEMENT), Washout (3 weeks) (OTHER), Second Intervention (14 days) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02838979?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02838979 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
Metformin in Kidney Disease
COMPLETED · Phase 2
-
Biomarker Guided Therapies in Stage A/B Heart Failure
COMPLETED · Phase 2
-
Reduction of Smoking in Cardiac Disease Patients
COMPLETED · Phase 2
-
The Fibrin Pad Cardiovascular Study
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.